GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes
ConditionType 1 Diabetes (T1D)
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity of Bern
About this trial
Blood glucose management in type 1 diabetes (T1D) remains a challenge, with only \~30% of adults within the recommended consensus guidelines. Novel drugs like glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs have emerged as promising add-ons to insulin in T1D.
This application has been designed to test in a prospective study whether adding a new medicine called tirzepatide (GIP/GLP-1RA) to the usual insulin therapy would make a difference for people with T1D in terms of better glucose control.
Eligibility criteria
Qualifiers
Participants with diagnosed T1D for at least 12 months.
Aged between 18 to 65 years old (inclusive).
Currently on AID therapy for at least three months.
HbA1C higher or equal to 6.5% and less or equal to 10%.
Disqualifiers
History of diabetic ketoacidosis requiring hospitalization in the past six months.
History of severe hypoglycemic event (Level 3, defined as seizure or loss of consciousness) in the past six months.
Uncontrolled Diabetic retinopathy or maculopathy
Severe gastroparesis.
Trial design
Treatments tested in this trial
- Tirzepatide
Treatment groups
42 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Bern
Lead sponsor
Kantonsspital Olten
Collaborator
Luzerner Kantonsspital
Collaborator
Clinique des Grangettes, Chêne-Bougeries
Collaborator
Source ClinicalTrials.gov